These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12739987)

  • 21. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica.
    Pérez V; Saénz D; Madriz J; Harhay M; Feoli J; Castro M; Odio C
    Int J Infect Dis; 2011 Aug; 15(8):e569-75. PubMed ID: 21733727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.
    Nicolau DP; Freeman CD; Belliveau PP; Nightingale CH; Ross JW; Quintiliani R
    Antimicrob Agents Chemother; 1995 Mar; 39(3):650-5. PubMed ID: 7793867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity?
    Zhanel GG; Ariano RE
    Ren Fail; 1992; 14(1):1-9. PubMed ID: 1561384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
    Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of aminoglycoside serum assays on clinical decisions and renal toxicity.
    Arroyo JC; Milligan WL; Davis J; Mitchell D
    South Med J; 1986 Mar; 79(3):272-6. PubMed ID: 3513326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [PK/PD modeling of aminoglycoside nephrotoxicity].
    Rougier F; Corvaisier S; Ducher M; Claude D; Jelliffe RW; Maire P
    Pathol Biol (Paris); 2003 Jun; 51(4):234-6. PubMed ID: 12853000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
    de Jager P; van Altena R
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides.
    Raveh D; Kopyt M; Hite Y; Rudensky B; Sonnenblick M; Yinnon AM
    QJM; 2002 May; 95(5):291-7. PubMed ID: 11978900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity.
    Smith CR; Lipsky JJ; Lietman PS
    Antimicrob Agents Chemother; 1979 Jun; 15(6):780-2. PubMed ID: 475363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.
    Williams PJ; Hull JH; Sarubbi FA; Rogers JF; Wargin WA
    J Clin Pharmacol; 1986 Feb; 26(2):79-86. PubMed ID: 3950060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and toxicity of aminoglycoside therapy in the elderly: combined effect of both once-daily regimen and therapeutic drug monitoring].
    Foltz F; Ducher M; Rougier F; Coudray S; Bourhis Y; Druguet M; Maire P
    Pathol Biol (Paris); 2002 May; 50(4):227-32. PubMed ID: 12085667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?
    Barclay ML; Kirkpatrick CM; Begg EJ
    Clin Pharmacokinet; 1999 Feb; 36(2):89-98. PubMed ID: 10092956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aminoglycosides use in patients over 75 years old.
    Fraisse T; Gras Aygon C; Paccalin M; Vitrat V; De Wazieres B; Baudoux V; Lechiche C; Vicens A; Sotto A; Pagani L; Gaillat J; Forestier E; Gavazzi G
    Age Ageing; 2014 Sep; 43(5):676-81. PubMed ID: 24590569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aminoglycoside prescription, therapeutic monitoring and nephrotoxicity at a university hospital in Saudi Arabia.
    Eltahawy AT; Bahnassy AA
    J Chemother; 1996 Aug; 8(4):278-83. PubMed ID: 8873833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gentamicin in neonatal infection: once versus twice daily dosage.
    Chotigeat U; Narongsanti A; Ayudhya DP
    J Med Assoc Thai; 2001 Aug; 84(8):1109-15. PubMed ID: 11758844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
    Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once versus twice daily amikacin in neonates: prospective study on toxicity.
    Kotze A; Bartel PR; Sommers DK
    J Paediatr Child Health; 1999 Jun; 35(3):283-6. PubMed ID: 10404451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of two amikacin dosing regimens in paediatric surgical patients.
    Forsyth NB; Botha JH; Hadley GP
    Ann Trop Paediatr; 1997 Sep; 17(3):253-61. PubMed ID: 9425382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
    Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
    Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.